{"id":"W2954573235","doi":"10.1097/01.ogx.0000458794.60509.a8","title":"Anti-Angiopoietin Therapy With Trebananib for Recurrent Ovarian Cancer (TRINOVA-1)","year":2014,"lang":"en","type":"article","venue":"Obstetrical & Gynecological Survey","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Bevacizumab; Ovarian cancer; Adverse effect; Angiogenesis; Vascular endothelial growth factor; Oncology; Internal medicine; Progression-free survival; Cancer; Endometrial cancer; Chemotherapy; Gastroenterology; VEGF receptors","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005489678,0.000365293,0.0009017555,0.0001173501,0.000163127,0.00005630861,0.0001799568,0.0002545337,0.001208005],"category_scores_gemma":[0.001821032,0.0002127028,0.0002525259,0.0008470911,0.0001116952,0.00004616888,0.00004231043,0.0002516708,0.00005368546],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003364015,"about_ca_system_score_gemma":0.0001408392,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003762061,"about_ca_topic_score_gemma":0.0002539051,"domain_scores_codex":[0.9974287,0.0002959361,0.00042902,0.0007756714,0.0004073833,0.0006633269],"domain_scores_gemma":[0.9943469,0.004354111,0.0001576852,0.0004210908,0.0003052044,0.0004149692],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00142143,0.002816617,0.7095739,0.00003466714,0.0003542193,0.00004060589,0.00003025102,0.00001601255,0.00004477911,0.001141653,0.0052678,0.2792581],"study_design_scores_gemma":[0.007667778,0.006029821,0.8837239,0.00003877385,0.0001102266,0.000005626831,0.000006833642,0.0001113082,0.0002916169,0.00007633068,0.1016561,0.0002817233],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9728182,0.007264227,0.002122311,0.008043732,0.001589367,0.00387069,0.0003264774,0.0003125284,0.003652444],"genre_scores_gemma":[0.994141,0.0009179135,0.001966893,0.001381598,0.0002552544,0.0006491843,0.0001695368,0.00004355642,0.0004750922],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2789764,"threshold_uncertainty_score":0.999705,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0637762528799003,"score_gpt":0.3192112720024464,"score_spread":0.2554350191225461,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}